To keep research teams informed of the latest updates to ClinicalTrials.gov, the University at Buffalo Clinical and Translational Science Institute (CTSI) will be providing news about the ...

MYC targeted therapies offer significant market opportunities, driven by their potential as oncogenic drivers in diverse tumors. The field sees growing R&D on innovative platforms, early-stage ...

The report identifies key market opportunities by highlighting prominent clinical trial locations, understanding trial success rates, and analyzing global enrollment trends. It aids in strategic ...

The "DNA Cancer Vaccine Clinical Trials, Development Technology Platforms & Market Opportunity Outlook 2026" report has been added to ResearchAndMarkets.com's offering. The global impact of cancer ...

CTSI Open Research Office sessions feature important topics that can aid those involved in the research process. Through the Open Research Office sessions, Clinical Research Facilitators collaborate ...

Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...

The main market opportunities lie in developing precise CD22 targeted therapies for blood cancers, with over 20 ongoing clinical trials. Innovative technologies like TALEN® are enhancing cell-based ...

CNSide Diagnostics will present data from the FORESEE trial showcasing the CNSide CSF Assay Platform’s utility in diagnosing and guiding clinical decision making for breast cancer and non-small cell ...

Large cell carcinoma is aggressive, requiring early detection through imaging and biopsy for optimal treatment outcomes.

AUSTIN, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (“Plus” or the “Company”), will present data from ...

POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of ...